Roche

Roche FY10

FY Revenues: $45.6 billion (+1%)

FY Earnings: $8.6 billion (+9%)

Comments: The company weathered the absence of Tamiflu revenues to post slight overall FY growth. Pharmaceutical sales dropped 2% to $35.6 billion. U.S. pharma sales dipped slightly to $13.5 billion, while Western Europe dropped 5% to $9.1 billion. International pharma sales (non-U.S., Western Europe or Japan) were up 8% to $8.8 billion. The company contends that U.S. healthcare reform and European austerity measures led to a $337 million hit in revenues. Avastin sales in the U.S. were flat at $3.1 bilion, while Lucentis sales rose 27% to $1.4 billion.